Compare iShares Global Tech ETF (IXN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares Global Tech ETF trades at $136.94, while Recursion Pharmaceuticals Inc trades at $3.04 (market cap $1.53B). The key difference: iShares Global Tech ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IXN | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $149.74 | $6.79 |
52-Week Low | $94.04 | $2.84 |
Market Cap | — | $1.53B |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $132.95 with minimal daily movement (+0.25%). Technical indicators show a neutral to bearish bias with mixed signals from moving averages and oscillators. The stock faces resistance near $139-$141 while finding support around $133-$136. Recent analysis highlights strong technology sector exposure but cautions about elevated valuations and concentration risks in the portfolio.
The outlook remains cautious as current price levels reflect significant optimism about AI-driven growth. Investment opportunity lies in continued technology sector leadership, while risks include valuation concerns and sector concentration. Analyst sentiment leans neutral with expectations for clearer earnings growth catalysts before more bullish positioning.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
